NGM Biopharmaceuticals, Inc. (NGM)
NGM moved a median of +0.60% 30 minutes after news, and 0.00% by the close. How NGM actually reacts to news — the realized, point-in-time move the market made, measured across 95 labeled events over the last three years with zero look-ahead.
NGM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 62 |
| 30-min | +0.60% | 71% | 63 |
| 60-min | 0.00% | 48% | 63 |
| to close | 0.00% | 41% | 63 |
| Middle 50% of NGM reactions | 0.00% to +1.72% |
|---|---|
| Median reaction (30-min) | +0.60% |
| Measured reactions | 95 |
Half of all NGM Biopharmaceuticals, Inc. news events land between +0.00% and +1.72% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when NGM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NGM's baseline. Nothing else.
Recent NGM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Xaira Therapeutics Announces the Appointment of Jeff Jonker as President and Chief Operating Officer | Press release | Business Wire | — | — | |
| Form 15-12G NGM BIOPHARMACEUTICALS | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form EFFECT NGM BIOPHARMACEUTICALS | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form 8-K NGM BIOPHARMACEUTICALS For: Apr 05 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM NGM BIOPHARMACEUTICALS | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS NGM BIOPHARMACEUTICALS | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| NGM Bio Announces Closing of Tender Offer | Press release | GlobeNewswire | — | — | |
| Form 10-K/A NGM BIOPHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | — | |
| NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting | Press release | GlobeNewswire | +0.32% | +0.00% | |
| SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EGLE, X, PGTI, NGM | Press release | PR Newswire | — | -0.65% | |
| Form 10-K NGM BIOPHARMACEUTICALS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +0.65% | |
| Form 8-K NGM BIOPHARMACEUTICALS For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.65% | |
| NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results | Press release | GlobeNewswire | +0.00% | +0.65% | |
| SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates EVRI, MDC, NGM, JNPR | Press release | PR Newswire | +0.65% | -0.65% | |
| Form 8-K NGM BIOPHARMACEUTICALS For: Feb 25 | SEC filing · Form 8-K | SEC EDGAR | -0.65% | +6.54% | |
| NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP | Press release | GlobeNewswire | -1.94% | -1.61% | |
| NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders | Press release | Business Wire | +0.00% | -0.33% | |
| NGM Bio to Participate in the Cowen 44th Annual Health Care Conference | Press release | GlobeNewswire | +0.61% | +17.79% | |
| Form 8-K NGM BIOPHARMACEUTICALS For: Jan 18 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | +1.59% | |
| NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference | Press release | GlobeNewswire | -0.73% | -2.92% | |
| NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need | Press release | GlobeNewswire | +1.97% | -1.18% | |
| Form 8-K NGM BIOPHARMACEUTICALS For: Dec 28 | SEC filing · Form 8-K | SEC EDGAR | -5.14% | +16.82% | |
| Form 8-K NGM BIOPHARMACEUTICALS For: Dec 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -5.01% | |
| NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting® | Press release | GlobeNewswire | +2.62% | -6.46% | |
| NGM Bio to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +3.23% | +0.21% | |
| Form 10-Q NGM BIOPHARMACEUTICALS For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +6.33% | +6.33% | |
| Form 8-K NGM BIOPHARMACEUTICALS For: Nov 02 | SEC filing · Form 8-K | SEC EDGAR | +6.33% | +6.33% | |
| NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights | Press release | GlobeNewswire | +6.33% | +6.33% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NGM section they belong to.
Where else NGM is measured.
NGM earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is NGM Biopharmaceuticals, Inc.'s median reaction calculated?
Every labeled NGM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 95 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 71% of NGM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NGM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.